Clinical Trials

BreastCNSGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

12 enrolled 12 charts

Pdgfra-Associated Chronic Eosinophilic Leukemia, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Testicular Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT01173679 2017-04-14

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

10 enrolled 6 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01449344 2017-03-07

(R-HAD)

Phase 3 Unknown

128 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT02420938 2016-12-06

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Withdrawn

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01871675 2016-07-11

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Phase 1 Completed

48 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT01421173 2015-11-18

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Phase 1 Completed

78 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT00547534 2015-08-06

BVR

31 enrolled 9 charts

LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Non-Hodgkin, Recurrence

NCT00087009 2013-03-19

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Phase 1 Terminated

3 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoproliferative Disorders, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

NCT00968331 2012-08-27

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

25 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00071396 2012-08-07

Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders

48 enrolled 5 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00509379 2011-01-28

LYM-2023

48 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT00393107 2006-10-26

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

54 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence

NCT00385125 2006-10-06

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Phase 2 Unknown

30 enrolled

Lymphoma, Non-Hodgkin, Recurrence

NCT00180895 2006-09-11

Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL

40 enrolled